SAN DIEGO--(BUSINESS WIRE)--Nov. 12, 2018--
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic
testing solutions, cellular-based virology assays and molecular
diagnostic systems, announced today that it will present at the 30th
Annual Piper Jaffray Healthcare Conference, to be held at the Lotte New
York Palace hotel in New York, New York on Wednesday, November 28, 2018.
Douglas Bryant, president and chief executive officer, and Randy
Steward, chief financial officer, will present that day at 8:30 a.m.
Eastern time (5:30 a.m. Pacific time) with a question and answer session
scheduled during the presentation. The company will discuss business and
financial developments and trends. The company's statements may contain
or constitute material information that has not been previously
disclosed.
A live webcast and audio archive of each presentation will be available
via the Investor Relations section of the company’s Web site at http://ir.quidel.com
or by clicking on the following link:
https://event.webcasts.com/starthere.jsp?ei=1220637&tp_key=dfa1b7fdf3
Participants should allow approximately five to ten minutes prior to the
presentation's start time to visit the site and download any streaming
media software needed to listen to the Internet webcast. A replay of the
webcast will also be available on the company’s Web site for 14 days.
About Quidel Corporation
Quidel Corporation serves to enhance the health and well-being of people
around the globe through the development of diagnostic solutions that
can lead to improved patient outcomes and provide economic benefits to
the healthcare system. Marketed under the Sofia®, QuickVue®,
D3® Direct Detection, Thyretain®, Triage®
and InflammaDry® leading brand names, as well as under the
new Solana®, AmpliVue® and Lyra®
molecular diagnostic brands, Quidel’s products aid in the detection and
diagnosis of many critical diseases and conditions, including, among
others, influenza, respiratory syncytial virus, Strep A, herpes,
pregnancy, thyroid disease and fecal occult blood. Quidel's recently
acquired Triage® system of tests comprises a comprehensive
test menu that provides rapid, cost-effective treatment decisions at the
point-of-care (POC), offering a diverse immunoassay menu in a variety of
tests to provide diagnostic answers for quantitative BNP, CK-MB,
d-dimer, myoglobin, troponin I and qualitative TOX Drug Screen. Quidel’s
research and development engine is also developing a continuum of
diagnostic solutions from advanced immunoassay to molecular diagnostic
tests to further improve the quality of healthcare in physicians’
offices and hospital and reference laboratories. For more information
about Quidel’s comprehensive product portfolio, visit quidel.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181112005689/en/
Source: Quidel Corporation
Quidel Contact:
Quidel Corporation
Randy Steward
Chief
Financial Officer
(858) 552-7931
or
Media and Investors
Contact:
Quidel Corporation
Ruben Argueta
(858) 646-8023
rargueta@quidel.com